IDEAYA Biosciences, Inc. filings document the regulatory record of a Nasdaq-listed precision oncology company developing targeted therapeutics and biomarker-directed cancer programs. Recent 8-K reports cover financial results, business updates, clinical data from the OptimUM darovasertib program, collaboration agreements involving investigational oncology assets, and Regulation FD corporate presentations.
The company’s SEC record also includes proxy materials for annual meeting governance, executive compensation and equity-plan matters. Registration and prospectus filings describe IDEAYA’s common stock, automatic shelf registration capacity, at-the-market sales arrangements and related capital-structure disclosures, alongside risk and pipeline information tied to its clinical-stage oncology portfolio.
IDEAYA Biosciences, Inc. granted a new equity award to its Chief Commercial Officer, Stuart Dorman. On January 30, 2026, he received a stock option for 155,000 shares of common stock with an exercise price of $32.19 per share.
According to the vesting schedule, 25% of the option vests on the first anniversary of January 1, 2026, and the remaining shares vest in equal monthly installments over the following three years, so the option becomes fully vested and exercisable on the fourth anniversary of the vesting commencement date.
IDEAYA Biosciences President and CEO Yujiro Hata received a grant of stock options reported as of January 30, 2026. The award covers 600,000 options to buy IDEAYA common stock at an exercise price of $32.19 per share.
According to the vesting terms, 25% of the options vest on the first anniversary of January 1, 2026, and the remaining portion vests in equal monthly installments over the following three years, so the grant becomes fully vested on the fourth anniversary of that date.
IDEAYA Biosciences SVP and General Counsel Douglas B. Snyder reported routine equity awards and employee share purchases. On 05/30/2025 and 11/28/2025, he acquired 1,039 and 1,041 shares of common stock, respectively, at $16.9065 per share under the company’s Employee Stock Purchase Plan, bringing his directly held common stock to 2,080 shares.
On 01/30/2026, he received a stock option for 130,000 shares of common stock at an exercise price of $32.19. The option vests 25% on the first anniversary of January 1, 2026, with the remaining shares vesting in equal monthly installments over the following three years until fully vested on the fourth anniversary.
IDEAYA Biosciences officer Andres Ruiz Briseno reported new equity awards and share acquisitions. He acquired 682 common shares on 11/29/2024 at $23.256 and 1,253 shares on 11/28/2025 at $16.9065 under the company’s Employee Stock Purchase Plan, bringing his direct holdings to 26,466 shares.
He was also granted a stock option for 80,000 shares of common stock at an exercise price of $32.19 on 01/30/2026. According to the grant terms, 25% of the option vests on the first anniversary of January 1, 2026, with the remaining shares vesting in equal monthly installments over the following three years.
IDEAYA Biosciences filed an 8-K describing a business update and outlining key corporate objectives for 2026 that it plans to present at the 44th Annual J.P. Morgan Healthcare Conference. The company highlights plans to advance four registrational trials, including IDE849, a Phase 1 DLL3 TOP1 antibody‑drug conjugate being developed as a monotherapy in neuroendocrine cancer, and darovasertib in both pre‑metastatic and metastatic uveal melanoma. The objectives span several focus areas such as darovasertib in uveal melanoma, ADC and DNA damage response combinations, the MTAP pathway, and next‑generation therapies, along with broader corporate goals. The filing also reiterates that these plans and anticipated timelines are forward‑looking and subject to clinical, regulatory, and operational risks.
IDEAYA Biosciences, Inc. filed a current report to note that it has posted an updated corporate presentation to the investor section of its website and furnished the same presentation as Exhibit 99.1. The presentation is dated January 12, 2026 and is intended to provide summary information about the company.
The company states that this information is being furnished under a disclosure item for investor presentations, not filed, so it is not subject to certain liability provisions of the securities laws and will not be automatically incorporated into other SEC filings. The presentation includes a Safe Harbor Statement addressing forward-looking statements.
Federated Hermes, Inc. filed Amendment No. 3 to a Schedule 13G reporting beneficial ownership of 3,395,771 shares of IDEAYA Biosciences, Inc. common stock, representing 3.87% of the class as of 12/31/2025. The same share amount and percentage are reported for the Voting Shares Irrevocable Trust, and for Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue, reflecting shared or sole voting and dispositive powers as disclosed on each cover page.
Federated Hermes, the trust, and the individual filers state that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of IDEAYA. They also declare, in accordance with Rule 13d-4, that this filing should not be construed as an admission that any of them is the beneficial owner of securities held by the managed funds, and they expressly disclaim beneficial ownership of those securities. The filing indicates ownership of 5 percent or less of IDEAYA’s common stock.
IDEAYA Biosciences reports that GlaxoSmithKline Intellectual Property (No. 4) Limited has elected to terminate their Collaboration, Option and License Agreement dated June 15, 2020. The termination becomes effective on March 9, 2026, ninety days after GSK’s written notice on December 9, 2025.
During this 90-day transition period, GSK will transfer the Werner Helicase (IDE275) and Pol Theta (IDE705) clinical programs back to IDEAYA. The company plans to evaluate strategic options for these two programs in 2026 and states that this update does not change its expectation of a cash runway into 2030.
IDEAYA also includes forward-looking statements highlighting risks typical for drug development, such as early-stage program uncertainty, clinical and regulatory processes, manufacturing and commercialization challenges, pricing and reimbursement negotiations, protection of intellectual property, and factors that could affect whether existing cash is sufficient to fund operations.
IDEAYA Biosciences (IDYA) reported Q3 2025 results, driven by collaboration revenue recognized from its August 2025 Servier license. Total revenue was $207.834 million, all from collaboration, yielding net income of $119.244 million versus a loss a year ago. Research and development expense was $82.993 million and general and administrative expense was $16.389 million.
Liquidity strengthened: as of September 30, 2025, cash, cash equivalents and marketable securities were approximately $1.14 billion. Management believes this will fund planned operations for at least 12 months from issuance of the statements. Basic EPS was $1.35 on 88.5 million weighted-average shares. The company also raised $25.0 million net during the nine months via its at-the-market program (984,000 shares at a weighted average price of ~$26). Shares outstanding were 87,666,408 as of October 31, 2025.
The quarter reflects the Servier License Agreement for darovasertib outside the U.S., under which Servier paid a $210.0 million upfront; $207.8 million was recognized as collaboration revenue in Q3.
IDEAYA Biosciences, Inc. furnished a current report describing that it announced its financial results for the third quarter ended September 30, 2025. The company did this through a press release dated November 4, 2025, which is included as Exhibit 99.1.
The report clarifies that the earnings information and the press release are being furnished, not filed, so they are not automatically subject to certain Exchange Act liabilities or incorporated into other securities law filings unless specifically referenced.